Clinical Trial Update: Infliximab in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated infliximab in patients with myelodysplastic syndromes; the trial sponsored by EORTC has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED